PTEN and glioblastoma: Other approaches, such as anti-angiogenic therapies, might also benefit patients before exposure to immunotherapeutics.11 Interestingly, PTEN-deficient glioblastomas overexpressed the CD44 cell-surface adhesion receptor and had a more compact tumour-cell phenotype that could exclude vascularisation and immune cells from the TME than wild-type glioblastomas,22 rendering them less likely to respond to ICI.